Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 150 versus ULTRAVIST 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 150 versus ULTRAVIST 300.
ULTRAVIST 150 vs ULTRAVIST 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonionic iodinated contrast medium that attenuates X-rays, enhancing vascular and tissue contrast due to iodine content. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Nonionic iodinated contrast medium that attenuates X-rays, providing vascular and tissue enhancement for imaging.
Intravascular administration: 1-2 mL/kg of ULTRAVIST 150 (150 mg iodine/mL) as a bolus or rapid infusion. Typical adult dose ranges from 50-200 mL depending on procedure and patient weight. Not to exceed 7.5 mL/kg.
Intravenous: 1.0-2.0 mL/kg (300-600 mg iodine/kg) body weight; maximum 200 mL per procedure. Intra-arterial: varies by procedure.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours) in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment)
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged in renal impairment (up to 10 hours in severe cases).
Primarily renal (glomerular filtration, >95% of injected dose excreted unchanged in urine within 24 hours; negligible biliary/fecal excretion <2%)
Renal: 95-100% as unchanged drug within 24 hours; biliary/fecal: <1%.
Category C
Category C
Radiographic Contrast Agent (Iodinated Non-Ionic)
Radiographic Contrast Agent (Iodinated Non-Ionic)